NCT04284774 2025-12-04Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialNational Cancer Institute (NCI)Phase 2 Active not recruiting5 enrolled 9 charts